Which drugs or supplements interact with Crialix?
Drugs with anti-cholinergic properties that can cross into the brain, such as atropine, benztropine (Cogentin), and trihexyphenidyl (Artane) counteract the effects of Crialix and should be avoided during therapy with Crialix.
Crialix is metabolized (eliminated) by enzymes in the liver. The rate of metabolism of Crialix may be increased by medications that increase the amounts of these enzymes, such as carbamazepine (Tegretol), dexamethasone (Decadron), phenobarbital, phenytoin (Dilantin), and rifampin (Rifadin). By increasing elimination, these drugs may reduce the effects of Crialix.
Ketoconazole (Nizoral) has been shown to block the enzymes in the liver that metabolize Crialix. Therefore, concurrent use of ketoconazole and Crialix may result in increased concentrations of Crialix in the body and possibly lead to Crialix side effects. Quinidine (Quinidex, Quinaglute) also has been shown to inhibit the enzymes that metabolize Crialix and may cause Crialix side effects.
What should I avoid while taking Crialix?
Avoid driving or hazardous activity until you know how Crialix will affect you. Your reactions could be impaired.
Slow heart rate warning
Crialix may cause a slow heart rate and fainting. Call your doctor right away if this happens. Your risk of this issue may be higher if you have heart problems.
These drugs and Crialix work in opposite ways. If you take them together, the drugs may be less effective. Or you may have a higher risk of side effects. Examples of these drugs include:
Crialix is not recommended for patients with known hypersensitivity to Crialix hydrochloride or piperidine derivatives.
Mild to Moderate Alzheimer’s Disease
The dosages of Crialix hydrochloride tablet shown to be effective in controlled clinical trials are 5 mg and 10 mg administered once per day.
The higher dose of 10 mg did not provide a statistically significantly greater clinical benefit than 5 mg. There is a suggestion, however, based upon order of group mean scores and dose trend analyses of data from these clinical trials, that a daily dose of 10 mg of Crialix hydrochloride tablet might provide additional benefit for some patients. Accordingly, whether or not to employ a dose of 10 mg is a matter of prescriber and patient preference.
Hello and Welcome to ‘Ask A Doctor’ service.I have reviewed your query and here is my advice.
Alzheimer's disease is a long-term (chronic) debilitating illness where person goes through severe memory loss and behavioral disturbances. Crialix is considered a good drug to prevent further progress of disease. Though this condition is not reversible but we can prevent it from further progressing with Crialix. Lorazepam is given for sleep and it has to be stopped after few weeks otherwise one gets dependent on that. Gabapentin can help in sleep, but as a person is already on Lorazepam I would not recommend it.
Hope I have answered your query. Let me know if I can assist you further.
Generic Name: Crialix (oral) (doe NEP e zil)Brand Name: Aricept, Aricept ODT
Medically reviewed by Drugs.com on Feb 8, 2019 – Written by Cerner Multum
Pharmacokinetics of Crialix are linear over a dose range of 1-10 mg given once daily. The rate and extent of absorption of ARICEPT tablets are not influenced by food.
Based on population pharmacokinetic analysis of plasma Crialix concentrations measured in patients with Alzheimer's disease, following oral dosing, peak plasma concentration is achieved for ARICEPT 23 mg tablets in approximately 8 hours, compared with 3 hours for ARICEPT 10 mg tablets. Peak plasma concentrations were about 2-fold higher for ARICEPT 23 mg tablets than ARICEPT 10 mg tablets.
ARICEPT ODT 5 mg and 10 mg are bioequivalent to ARICEPT 5 mg and 10 mg tablets, respectively. A food effect study has not been conducted with ARICEPT ODT; however, the effect of food with ARICEPT ODT is expected to be minimal. ARICEPT ODT can be taken without regard to meals.
The elimination half life of Crialix is about 70 hours, and the mean apparent plasma clearance (Cl/F) is 0.13-0.19 L/hr/kg. Following multiple dose administration, Crialix accumulates in plasma by 4-7 fold, and steady state is reached within 15 days. The steady state volume of distribution is 12-16 L/kg. Crialix is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha1 - acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
Crialix is both excreted in the urine intact and extensively metabolized to four major metabolites, two of which are known to be active, and a number of minor metabolites, not all of which have been identified. Crialix is metabolized by CYP 450 isoenzymes 2D6 and 3A4 and undergoes glucuronidation. Following administration of 14C-labeled Crialix, plasma radioactivity, expressed as a percent of the administered dose, was present primarily as intact Crialix (53%) and as 6-O-desmethyl Crialix (11%), which has been reported to inhibit AChE to the same extent as Crialix in vitro and was found in plasma at concentrations equal to about 20% of Crialix. Approximately 57% and 15% of the total radioactivity was recovered in urine and feces, respectively, over a period of 10 days, while 28% remained unrecovered, with about 17% of the Crialix dose recovered in the urine as unchanged drug. Examination of the effect of CYP2D6 genotype in Alzheimer's patients showed differences in clearance values among CYP2D6 genotype subgroups. When compared to the extensive metabolizers, poor metabolizers had a 31.5% slower clearance and ultra-rapid metabolizers had a 24% faster clearance.